The Recap: August 2024

At Velocity, we've always strived to recognize key market signals and be responsive to client needs. We continually face an exciting challenge: how do we expand while remaining agile?

One part of the answer lies in our Growth and Development (G&D) team which focuses on delivering perfectly fit solutions to emerging and mid-sized companies.

• For small to mid-sized CROs, our G&D team helps ensure our size and capabilities can be a game-changer in winning bids.
• For startup biotechs and mid-sized Sponsors, we accelerate enrollment and offer cost savings through direct partnership — the efficiencies are immediately felt during feasibility, site selection, contracting, and startup.

This approach ensures top-tier clinical trial support for companies at every growth stage, not just the largest players.

Diversity also helps us remain flexible — diversity not just geographically, but in the range of our sites, the patients we reach, and the breadth of our collective experience. We've intentionally diversified therapeutically, operationally, and experientially, allowing us to support an ever-expanding spectrum of clinical trials.

Recent developments highlight this strategy — in July, we:

• Welcomed Mike Zaranek as CFO, bringing a tremendous level of industry expertise to Velocity's already veteran leadership team.
• Continued our expansion in Europe with new facilities in High Wycombe, UK, and Leipzig, Germany.
• Added a rheumatology site in St. Louis, Missouri, boosting our capabilities in arthritis, lupus, and more.
• Facilitated over $1.1 million in patient stipend payments using our VISION technology, streamlining processes for all involved.

We continue to centralize and elevate our capabilities, integrating technology, operations, and recruitment efforts to provide a more cohesive experience for clients and patients alike.

Thank you for your partnership, and for helping us reimagine the way trials can be delivered at every scale.

Jennifer Carl

Vice President, Growth & Development

[email protected]

Mike Zaranek Appointed Chief Financial Officer of Velocity

Mike brings nearly three decades of experience in the life-sciences industry in senior financial and corporate development leadership roles, having previously held roles at IQVIA and Science 37. He will direct the company’s financial goals and accounting, and advise on the Velocity's strategic direction.

Read More >

Velocity's European Expansion Continues

Our sites in Leipzig, Germany and High Wycombe, UK, have recently relocated to larger, more accessible facilities. The moves enable us to accommodate a higher volume of patient visits and provide enhanced capabilities in purpose-built sites.

See the Sites >

New Site Announced in St. Louis, Missouri

An elected Fellow of the American College of Rheumatology, Sona Kamat, MD, FACR, will serve as Principal Investigator for clinical trials at Velocity. The site will provide specialized support for rheumatology research, as well as a growing array of internal medicine and multi-therapeutic trials.

Read More >

VISION Reaches $1.1 Million in Patient Study Stipends Paid

After the app launched just a year ago, Velocity has now paid more than $1.1 million in study stipends through our VISION Engage app. For patients, Velocity Pay delivers prompt, secure in-app payments, as well as enhanced visibility and flexibility.

Read More >

Featured Video: William Cromwell, MD, FAHA, FNLA, Cardiometabolic CARE Council Leader

Heart disease remains the leading cause of death worldwide. The proliferation of heart issues — paired with lifestyle factors that complicate patient recruitment and study design — reflect an urgent need for expert-led clinical trials.

Featuring: William Cromwell, MD, FAHA, FNLA